slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 91,861-91,890
Pages 3,685
Rows per page 30
Component
91,861-91,890 of 110,539
38
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
39
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
40
The fourth agenda item is highlighted with a blue circle, indicating the current or primary focus of the presentation.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
45
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
49
The table includes both financial figures in millions and vehicle counts in thousands.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Mece Breakdown1 hit
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
10
The slide illustrates the interaction between THIO (telomere targeting) and standard checkpoint inhibitor therapies.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo across efficacy, safety, and administration metrics.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
15
The slide compares the safety profile of THIO against standard of care (SOC) chemotherapy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
17
Data presented in a table format with footnotes explaining the methodology for DCR calculation.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
19
Clinical trial data visualization showing patient-level outcomes over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
24
Includes two line charts showing tumor volume reduction and rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
25
The slide compares clinical trial data for three different treatment regimens in CRC patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
27
The table compares an existing standard of care (Zepzelca) against the company's planned trial (THIO-102).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
07
The slide uses a numbered list structure to define the core pillars of the investment strategy.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Solution1 hit
08
The chart uses a dual-axis approach to show both per-share metrics and NAV growth over time.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
09
LMM stands for Lower Middle Market.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
10
LMM stands for Lower Middle Market.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Market Size1 hit
14
The slide outlines the three pillars of the company's regulatory structure: BDC, RIC, and SBIC.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
16
The slide uses a consistent layout of green name/title blocks paired with bulleted professional history.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
17
The chart highlights specific periods like the 'Recessionary Period' and 'COVID Pandemic Period' to demonstrate dividend stability.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
21
The chart uses a 3D pie representation to show a highly fragmented portfolio with no single industry dominating.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
29
Includes detailed footnotes explaining calculation methodologies for yield and interest rates.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
30
Includes detailed footnotes regarding calculation methodology for yields and interest rates.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
31
The chart displays 26 distinct industry segments with percentages ranging from 1% to 13%.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit